Files
Download Full Text (711 KB)
Publication Date
2024
Keywords
oregon, oaa 2024, psvmc
Disciplines
Medical Education | Pharmacy and Pharmaceutical Sciences | Pulmonology
Abstract
Abstract: Cisatracurium is a non-depolarizing neuromuscular blocking agent used for paralysis in paitents with acute respiratory distress syndrome on mechanical ventilation. Paralysis prevents ventilator dyssynchrony and reduces patient’s work of breathing, which decreases the risk of pneumothorax. On November 1, 2023, PSVMC critical care units transitioned from fixed dosing of cisatracurium for ARDS to a weight-based, titratable dosing protocol. A single-center retrospective cohort study demonstrated cisatracurium titrated using train-of-four was associated with similar ventilatory and clinical outcomes with three folds reduction in cisatracrurium dose in comparison to fixed dose strategy. The purpose of this project is to evaluate the drug utilization and cost savings of the newly implemented cisatracurium dosing strategy in comparison to the previous fixed dose protocol. This is a single-center, retrospective review of patients >18 years old who received cisatracurium for ventilation synchrony in ARDS in the intensive care unit. The primary endpoint is the average dose of cisatracurium administered. The secondary endpoints include duration on mechanical ventilator, length of ICU stay, length of hospital stay, dose of sedatives and analgesics needed during paralysis, ventilator settings prior to and during paralysis, and re-initiation of cisatracurium after discontinuation. Data was collected via EPIC SlicerDicer and manual patient chart review for cases between November 1, 2022 and February 29, 2024. A total of 14 patients were assessed during pre- and post-protocol change. Results and conclusions will be shared when the project is completed. (IRB approved)
Specialty/Research Institute
Graduate Medical Education
Specialty/Research Institute
Pulmonary Medicine
Specialty/Research Institute
Pharmacy
Included in
Medical Education Commons, Pharmacy and Pharmaceutical Sciences Commons, Pulmonology Commons
